Sang-Choong Roh1, Eun-Jin Park2, Miseon Shim3, Seung-Hwan Lee4. 1. Clinical Emotion and Cognition Research Laboratory, Inje University, Goyang, Republic of Korea. 2. Department of Psychiatry, Inje University, Ilsan-Paik Hospital, Juhwa-ro 170, Ilsanseo-gu, Goyang 411-706, Republic of Korea. Electronic address: uma99@hanmail.net. 3. Clinical Emotion and Cognition Research Laboratory, Inje University, Goyang, Republic of Korea; Department of Biomedical Engineering, Hanyang University, Seoul, Republic of Korea. 4. Clinical Emotion and Cognition Research Laboratory, Inje University, Goyang, Republic of Korea; Department of Psychiatry, Inje University, Ilsan-Paik Hospital, Juhwa-ro 170, Ilsanseo-gu, Goyang 411-706, Republic of Korea. Electronic address: lshpss@paik.ac.kr.
Abstract
BACKGROUND: Inattention is a common feature of major depressive disorder (MDD). The aim of this study was to explore the relationship between quantitative electroencephalography (qEEG) power of a specific band and inattention severity in patients with MDD. METHODS: EEG recordings of 73 patients with MDD were collected in during both eyes closed and eyes open conditions. Inattention was assessed by the inattention sub-scale of the Korean version of the Adult ADHD scale (K-AADHD). The severity of symptoms associated with depression and anxiety was assessed with the Hamilton Rating Scale for Anxiety (HAM-A), the Hamilton Rating Scale for Depression (HAM-D), and the Beck Depression Inventory (BDI). Multiple regression and Hayes mediation model were applied for the statistical analysis to verify the effects of clinical variables on inattention score. RESULTS: The beta (12-30Hz) and low gamma (30-50Hz) powers in fronto-central regions were negatively correlated with inattention scores. Symptom severity scores strongly predicted inattention scores; in particular, the BDI accounted for 23.9% of the variance. In mediation analysis, BDI fully mediated the path of anxiety to inattention. LIMITATIONS: The medication effect and comorbidity in our participants were not fully controlled. A subjective assessment tool was hired to measure inattention. CONCLUSIONS: Beta and low gamma power of the fronto-central regions might be a reliable measure of attention deficits in patients with MDD, which in turn, seems to be related to the severity of subjective depressive symptoms. Further work is needed to confirm this finding on larger, drug and comorbidity-free samples, and to test the clinical utility.
BACKGROUND: Inattention is a common feature of major depressive disorder (MDD). The aim of this study was to explore the relationship between quantitative electroencephalography (qEEG) power of a specific band and inattention severity in patients with MDD. METHODS: EEG recordings of 73 patients with MDD were collected in during both eyes closed and eyes open conditions. Inattention was assessed by the inattention sub-scale of the Korean version of the Adult ADHD scale (K-AADHD). The severity of symptoms associated with depression and anxiety was assessed with the Hamilton Rating Scale for Anxiety (HAM-A), the Hamilton Rating Scale for Depression (HAM-D), and the Beck Depression Inventory (BDI). Multiple regression and Hayes mediation model were applied for the statistical analysis to verify the effects of clinical variables on inattention score. RESULTS: The beta (12-30Hz) and low gamma (30-50Hz) powers in fronto-central regions were negatively correlated with inattention scores. Symptom severity scores strongly predicted inattention scores; in particular, the BDI accounted for 23.9% of the variance. In mediation analysis, BDI fully mediated the path of anxiety to inattention. LIMITATIONS: The medication effect and comorbidity in our participants were not fully controlled. A subjective assessment tool was hired to measure inattention. CONCLUSIONS: Beta and low gamma power of the fronto-central regions might be a reliable measure of attention deficits in patients with MDD, which in turn, seems to be related to the severity of subjective depressive symptoms. Further work is needed to confirm this finding on larger, drug and comorbidity-free samples, and to test the clinical utility.
Authors: Tian-Hang Zhou; Nora E Mueller; Kevin M Spencer; Sonal G Mallya; Kathryn Eve Lewandowski; Lesley A Norris; Deborah L Levy; Bruce M Cohen; Dost Öngür; Mei-Hua Hall Journal: Schizophr Res Date: 2018-05-26 Impact factor: 4.939
Authors: Diego Carlos Fernandez; P Michelle Fogerson; Lorenzo Lazzerini Ospri; Michael B Thomsen; Robert M Layne; Daniel Severin; Jesse Zhan; Joshua H Singer; Alfredo Kirkwood; Haiqing Zhao; David M Berson; Samer Hattar Journal: Cell Date: 2018-08-30 Impact factor: 41.582
Authors: Paolo Bazzigaluppi; Conner Adams; Margaret M Koletar; Adrienne Dorr; Aleksandra Pikula; Peter L Carlen; Bojana Stefanovic Journal: Front Mol Neurosci Date: 2018-09-13 Impact factor: 5.639